Epimab Biotherapeutics Announces Oral Presentation For EMB-06 (CND106) First-In-Human (FIH) Phase I Study In Multiple Myeloma At The American Society Of Hematology (ASH) 2024 Annual Meeting
Epimab Biotherapeutics Announces Oral Presentation For EMB-06 (CND106) First-In-Human (FIH) Phase I Study In Multiple Myeloma At The American Society Of Hematology (ASH) 2024 Annual Meeting . (MENAFN - GlobeNewsWire - Nasdaq) SHANGHAI, Dec. 06, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108962739/Epimab-Biotherapeutics-Announces-Oral-Presentation-For-EMB-06-CND106-First-In-Human-FIH-Phase-I-Study-In-Multiple-Myeloma-At-The-American-Society-Of-Hematology-ASH-2024-Annual-Meeting
2024-12-05
rss
(MENAFN - GlobeNewsWire - Nasdaq) SHANGHAI, Dec. 06, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific ...
Epimab Biotherapeutics Announces Oral Presentation For EMB-06 (CND106) First-In-Human (FIH) Phase I Study In Multiple Myeloma At The American Society Of Hematology (ASH) 2024 Annual Meeting